Comparative Effectiveness of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications vs. Usual Care
Increased Risk of Thromboembolic Events With rFVIIa Use for Adult Cardiac Surgery
There is evidence of moderate strength to suggest that the use of rFVIIa in adult cardiac surgery increases the rate of thromboembolic events when compared to usual care. Thus, current evidence of moderate strength (for thromboembolic events) or low strength (for all other outcomes) suggests that neither benefits nor harms substantially exceed each other for rFVIIa use in adult cardiac surgery.
- Yank V, Tuohy CV, Logan AC, et al. Comparative Effectiveness of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications vs. Usual Care, Comparative Effectiveness Review 21 (Prepared by Stanford–UCSF Evidence-based Practice Center under Contract No. 290-02-0017). Rockville, MD: Agency for Healthcare Research and Quality; May 2010. AHRQ Publication No. 10-EHC030-EF.
Your slide tray is being processed.